Methylation status of the E2 binding sites of HPV16 in cervical lesions determined with the Luminex® xMAP™ system

Virology

Volumn 422, Issue 2, 2012, Pages 357-365

  Snellenberg, Suzanne ^a   Schütze, Denise M ^a   Claassen Kramer, Debbie ^a   Meijer, Chris J L M ^a   Snijders, Peter J F ^a   Steenbergen, Renske D M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cervical cancer; DNA methylation; E2 binding site; E6 E7 deregulation; Human papillomavirus 16

Indexed keywords

E2BS1 PROTEIN; E2BS2 PROTEIN; E2BS3 PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANALYTIC METHOD; ARTICLE; BINDING SITE; CONTROLLED STUDY; DISEASE SEVERITY; DNA DETERMINATION; DNA METHYLATION; FEMALE; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN TISSUE; MIP LUMINEX SYSTEM; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; RELIABILITY; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX BIOPSY; UTERINE CERVIX CARCINOMA IN SITU;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CELLS, CULTURED; CERVICAL INTRAEPITHELIAL NEOPLASIA; DNA METHYLATION; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION, VIRAL; HUMAN PAPILLOMAVIRUS 16; HUMANS; LUMINESCENT MEASUREMENTS; METHYLATION; MIDDLE AGED; ONCOGENE PROTEINS, VIRAL; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS;

HUMAN PAPILLOMAVIRUS - 16; HUMAN PAPILLOMAVIRUS TYPE 16;

EID: 84855189776     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2011.11.006     Document Type: Article

References (67)

1. Androphy E.J., Lowy D.R., Schiller J.T. Bovine papillomavirus E2 trans-activating gene product binds to specific sites in papillomavirus DNA. Nature 1987, 325:70-73.
2. Badal V., Chuang L.S., Tan E.H., Badal S., Villa L.L., Wheeler C.M., Li B.F., Bernard H.U. CpG methylation of human papillomavirus type 16 DNA in cervical cancer cell lines and in clinical specimens: genomic hypomethylation correlates with carcinogenic progression. J. Virol. 2003, 77:6227-6234.
3. Baker C.C., Phelps W.C., Lindgren V., Braun M.J., Gonda M.A., Howley P.M. Structural and transcriptional analysis of human papillomavirus type 16 sequences in cervical carcinoma cell lines. J. Virol. 1987, 61:962-971.
4. Bellanger S., Tan C.L., Xue Y.Z., Teissier S., Thierry F. Tumor suppressor or oncogene? A critical role of the human papillomavirus (HPV) E2 protein in cervical cancer progression. Am J Cancer Res 2011, 1:373-389.
5. Bhattacharjee B., Sengupta S. CpG methylation of HPV 16 LCR at E2 binding site proximal to P97 is associated with cervical cancer in presence of intact E2. Virology 2006, 354:280-285.
6. Bhattacharjee B., Sengupta S. HPV16 E2 gene disruption and polymorphisms of E2 and LCR: some significant associations with cervical cancer in Indian women. Gynecol. Oncol. 2006, 100:372-378.
7. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev. 2002, 16:6-21.
8. Boyer S.N., Wazer D.E., Band V. E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res. 1996, 56:4620-4624.
9. Boyes J., Bird A. Repression of genes by DNA methylation depends on CpG density and promoter strength: evidence for involvement of a methyl-CpG binding protein. EMBO J. 1992, 11:327-333.
10. Brandsma J.L., Sun Y., Lizardi P.M., Tuck D.P., Zelterman D., Haines G.K., Martel M., Harigopal M., Schofield K., Neapolitano M. Distinct human papillomavirus type 16 methylomes in cervical cells at different stages of premalignancy. Virology 2009, 389:100-107.
11. Bulkmans N.W., Berkhof J., Rozendaal L., van Kemenade F.J., Boeke A.J., Bulk S., Voorhorst F.J., Verheijen R.H., van Groningen K., Boon M.E., Ruitinga W., van Ballegooijen M., Snijders P.J., Meijer C.J. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007, 370:1764-1772.
12. Chow L.T., Broker T.R. Papillomavirus DNA replication. Intervirology 1994, 37:150-158.
13. Cullen A.P., Reid R., Campion M., Lorincz A.T. Analysis of the physical state of different human papillomavirus DNAs in intraepithelial and invasive cervical neoplasm. J. Virol. 1991, 65:606-612.
14. Ding D.C., Chiang M.H., Lai H.C., Hsiung C.A., Hsieh C.Y., Chu T.Y. Methylation of the long control region of HPV16 is related to the severity of cervical neoplasia. Eur. J. Obstet. Gynecol. Reprod. Biol. 2009, 147:215-220.
15. Dixon E.P., Pahel G.L., Rocque W.J., Barnes J.A., Lobe D.C., Hanlon M.H., Alexander K.A., Chao S.F., Lindley K., Phelps W.C. The E1 helicase of human papillomavirus type 11 binds to the origin of replication with low sequence specificity. Virology 2000, 270:345-357.
16. Dong G., Broker T.R., Chow L.T. Human papillomavirus type 11 E2 proteins repress the homologous E6 promoter by interfering with the binding of host transcription factors to adjacent elements. J. Virol. 1994, 68:1115-1127.
17. Dowhanick J.J., McBride A.A., Howley P.M. Suppression of cellular proliferation by the papillomavirus E2 protein. J. Virol. 1995, 69:7791-7799.
18. Dunbar S.A. Applications of Luminex xMAP technology for rapid, high-throughput multiplexed nucleic acid detection. Clin. Chim. Acta 2006, 363:71-82.
19. Eriksson R., Jobs M., Ekstrand C., Ullberg M., Herrmann B., Landegren U., Nilsson M., Blomberg J. Multiplex and quantifiable detection of nucleic acid from pathogenic fungi using padlock probes, generic real time PCR and specific suspension array readout. J. Microbiol. Methods 2009, 78:195-202.
20. Fernandez A.F., Rosales C., Lopez-Nieva P., Grana O., Ballestar E., Ropero S., Espada J., Melo S.A., Lujambio A., Fraga M.F., Pino I., Javierre B., Carmona F.J., Acquadro F., Steenbergen R.D., Snijders P.J., Meijer C.J., Pineau P., Dejean A., Lloveras B., Capella G., Quer J., Buti M., Esteban J.I., Allende H., Rodriguez-Frias F., Castellsague X., Minarovits J., Ponce J., Capello D., Gaidano G., Cigudosa J.C., Gomez-Lopez G., Pisano D.G., Valencia A., Piris M.A., Bosch F.X., Cahir-McFarland E., Kieff E., Esteller M. The dynamic DNA methylomes of double-stranded DNA viruses associated with human cancer. Genome Res. 2009, 19:438-451.
21. Frattini M.G., Laimins L.A. Binding of the human papillomavirus E1 origin-recognition protein is regulated through complex formation with the E2 enhancer-binding protein. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:12398-12402.
22. Gaston K., Fried M. CpG methylation has differential effects on the binding of YY1 and ETS proteins to the bi-directional promoter of the Surf-1 and Surf-2 genes. Nucleic Acids Res. 1995, 23:901-909.
23. Gloss B., Bernard H.U. The E6/E7 promoter of human papillomavirus type 16 is activated in the absence of E2 proteins by a sequence-aberrant Sp1 distal element. J. Virol. 1990, 64:5577-5584.
24. Gravitt P.E., Kovacic M.B., Herrero R., Schiffman M., Bratti C., Hildesheim A., Morales J., Alfaro M., Sherman M.E., Wacholder S., Rodriguez A.C., Burk R.D. High load for most high risk human papillomavirus genotypes is associated with prevalent cervical cancer precursors but only HPV16 load predicts the development of incident disease. Int. J. Cancer 2007, 121:2787-2793.
25. Hegde R.S. The papillomavirus E2 proteins: structure, function, and biology. Annu. Rev. Biophys. Biomol. Struct. 2002, 31:343-360.
26. Holler M., Westin G., Jiricny J., Schaffner W. Sp1 transcription factor binds DNA and activates transcription even when the binding site is CpG methylated. Genes Dev. 1988, 2:1127-1135.
27. Hoppe-Seyler F., Butz K. Cellular control of human papillomavirus oncogene transcription. Mol. Carcinog. 1994, 10:134-141.
28. Hublarova P., Hrstka R., Rotterova P., Rotter L., Coupkova M., Badal V., Nenutil R., Vojtesek B. Prediction of human papillomavirus 16 e6 gene expression and cervical intraepithelial neoplasia progression by methylation status. Int. J. Gynecol. Cancer 2009, 19:321-325.
29. Jayshree R.S., Sreenivas A., Tessy M., Krishna S. Cell intrinsic & extrinsic factors in cervical carcinogenesis. Indian J. Med. Res. 2009, 130:286-295.
30. Jeon S., Lambert P.F. Integration of human papillomavirus type 16 DNA into the human genome leads to increased stability of E6 and E7 mRNAs: implications for cervical carcinogenesis. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:1654-1658.
31. Kalantari M., Calleja-Macias I.E., Tewari D., Hagmar B., Lie K., Barrera-Saldana H.A., Wiley D.J., Bernard H.U. Conserved methylation patterns of human papillomavirus type 16 DNA in asymptomatic infection and cervical neoplasia. J. Virol. 2004, 78:12762-12772.
32. Kalantari M., Lee D., Calleja-Macias I.E., Lambert P.F., Bernard H.U. Effects of cellular differentiation, chromosomal integration and 5-aza-2'-deoxycytidine treatment on human papillomavirus-16 DNA methylation in cultured cell lines. Virology 2008, 374:292-303.
33. Kim K., Garner-Hamrick P.A., Fisher C., Lee D., Lambert P.F. Methylation patterns of papillomavirus DNA, its influence on E2 function, and implications in viral infection. J. Virol. 2003, 77:12450-12459.
34. Lu J.Z., Sun Y.N., Rose R.C., Bonnez W., McCance D.J. Two E2 binding sites (E2BS) alone or one E2BS plus an A/T-rich region are minimal requirements for the replication of the human papillomavirus type 11 origin. J. Virol. 1993, 67:7131-7139.
35. Maitland N.J., Conway S., Wilkinson N.S., Ramsdale J., Morris J.R., Sanders C.M., Burns J.E., Stern P.L., Wells M. Expression patterns of the human papillomavirus type 16 transcription factor E2 in low- and high-grade cervical intraepithelial neoplasia. J. Pathol. 1998, 186:275-280.
36. Myohanen S., Wahlfors J., Janne J. Automated fluorescent genomic sequencing as applied to the methylation analysis of the human ornithine decarboxylase gene. DNA Seq. 1994, 5:1-8.
37. Nazarenko I., Kobayashi L., Giles J., Fishman C., Chen G., Lorincz A. A novel method of HPV genotyping using Hybrid Capture sample preparation method combined with GP5+/6+ PCR and multiplex detection on Luminex XMAP. J. Virol. Methods 2008, 154:76-81.
38. O'Connor M.J., Tan S.H., Tan C.H., Bernard H.U. YY1 represses human papillomavirus type 16 transcription by quenching AP-1 activity. J. Virol. 1996, 70:6529-6539.
39. Overmeer R.M., Henken F.E., Bierkens M., Wilting S.M., Timmerman I., Meijer C.J., Snijders P.J., Steenbergen R.D. Repression of MAL tumour suppressor activity by promoter methylation during cervical carcinogenesis. J. Pathol. 2009, 219:327-336.
40. Overmeer R.M., Henken F.E., Snijders P.J., Claassen-Kramer D., Berkhof J., Helmerhorst T.J., Heideman D.A., Wilting S.M., Murakami Y., Ito A., Meijer C.J., Steenbergen R.D. Association between dense CADM1 promoter methylation and reduced protein expression in high-grade CIN and cervical SCC. J. Pathol. 2008, 215:388-397.
41. Overmeer, R.M., Louwers, J.A., Meijer, C.J., van Kemenade, F.J., Hesselink, A.T., Daalmeijer, N.F., Wilting, S.M., Heideman, D.A., Verheijen, R.H., Zaal, A., van Baal, W.M., Berkhof, J., Snijders, P.J., Steenbergen, R.D., 2010. Combined CADM1 and MAL promoter methylation analysis to detect (pre-)malignant cervical lesions in high-risk HPV-positive women. Int. J. Cancer (Electronic publication ahead of print Dec 28).
42. Piyathilake C.J., Macaluso M., Alvarez R.D., Chen M., Badiga S., Edberg J.C., Partridge E.E., Johanning G.L. A higher degree of methylation of the HPV 16 E6 gene is associated with a lower likelihood of being diagnosed with cervical intraepithelial neoplasia. Cancer 2010, 117:957-963.
43. Rajeevan M.S., Swan D.C., Duncan K., Lee D.R., Limor J.R., Unger E.R. Quantitation of site-specific HPV 16 DNA methylation by pyrosequencing. J. Virol. Methods 2006, 138:170-176.
44. Sanders C.M., Maitland N.J. Kinetic and equilibrium binding studies of the human papillomavirus type-16 transcription regulatory protein E2 interacting with core enhancer elements. Nucleic Acids Res. 1994, 22:4890-4897.
45. Scheffner M., Werness B.A., Huibregtse J.M., Levine A.J., Howley P.M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990, 63:1129-1136.
46. Schwarz E., Freese U.K., Gissmann L., Mayer W., Roggenbuck B., Stremlau A., Zurhausen H. Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature 1985, 314:111-114.
47. Snijders P.J., Hogewoning C.J., Hesselink A.T., Berkhof J., Voorhorst F.J., Bleeker M.C., Meijer C.J. Determination of viral load thresholds in cervical scrapings to rule out CIN 3 in HPV 16, 18, 31 and 33-positive women with normal cytology. Int. J. Cancer 2006, 119:1102-1107.
48. Snijders P.J., van den Brule A.J., Jacobs M.V., Pol R.P., Meijer C.J. HPV DNA detection and typing in cervical scrapes. Methods Mol. Med. 2005, 119:101-114.
49. Steenbergen R.D., de Wilde J., Wilting S.M., Brink A.A., Snijders P.J., Meijer C.J. HPV-mediated transformation of the anogenital tract. J. Clin. Virol. 2005, 32(Suppl 1):S25-S33.
50. Steenbergen R.D., Kramer D., Braakhuis B.J., Stern P.L., Verheijen R.H., Meijer C.J., Snijders P.J. TSLC1 gene silencing in cervical cancer cell lines and cervical neoplasia. J. Natl. Cancer Inst. 2004, 96:294-305.
51. Steger G., Corbach S. Dose-dependent regulation of the early promoter of human papillomavirus type 18 by the viral E2 protein. J. Virol. 1997, 71:50-58.
52. Sun C., Reimers L.L., Burk R.D. Methylation of HPV16 genome CpG sites is associated with cervix precancer and cancer. Gynecol. Oncol. 2011, 121:59-63.
53. Sun Y.N., Lu J.Z., McCance D.J. Mapping of HPV-11 E1 binding site and determination of other important cis elements for replication of the origin. Virology 1996, 216:219-222.
54. Tan S.H., Baker C.C., Stunkel W., Bernard H.U. A transcriptional initiator overlaps with a conserved YY1 binding site in the long control region of human papillomavirus type 16. Virology 2003, 305:486-501.
55. Tan S.H., Leong L.E., Walker P.A., Bernard H.U. The human papillomavirus type 16 E2 transcription factor binds with low cooperativity to two flanking sites and represses the E6 promoter through displacement of Sp1 and TFIID. J. Virol. 1994, 68:6411-6420.
56. Tazi J., Bird A. Alternative chromatin structure at CpG islands. Cell 1990, 60:909-920.
57. Thain A., Jenkins O., Clarke A.R., Gaston K. CpG methylation directly inhibits binding of the human papillomavirus type 16 E2 protein to specific DNA sequences. J. Virol. 1996, 70:7233-7235.
58. Van Tine B.A., Kappes J.C., Banerjee N.S., Knops J., Lai L., Steenbergen R.D., Meijer C.L., Snijders P.J., Chatis P., Broker T.R., Moen P.T., Chow L.T. Clonal selection for transcriptionally active viral oncogenes during progression to cancer. J. Virol. 2004, 78:11172-11186.
59. van Vlodrop I.J., Niessen H.E., Derks S., Baldewijns M., Van Criekinge W., Herman J.G., van Engeland M. Analysis of promoter CpG island hypermethylation in cancer: location, location, location!. Clin. Cancer Res. 2011, 17:4225-4231.
60. Vester B., Wengel J. LNA (locked nucleic acid): high-affinity targeting of complementary RNA and DNA. Biochemistry 2004, 43:13233-13241.
61. Vinokurova S., von Knebel Doeberitz M. Differential methylation of the HPV 16 upstream regulatory region during epithelial differentiation and neoplastic transformation. PLoS One 2011, 6:e24451.
62. Vinokurova S., Wentzensen N., Kraus I., Klaes R., Driesch C., Melsheimer P., Kisseljov F., Durst M., Schneider A., von Knebel Doeberitz M. Type-dependent integration frequency of human papillomavirus genomes in cervical lesions. Cancer Res. 2008, 68:307-313.
63. Wells S.I., Francis D.A., Karpova A.Y., Dowhanick J.J., Benson J.D., Howley P.M. Papillomavirus E2 induces senescence in HPV-positive cells via pRB- and p21(CIP)-dependent pathways. EMBO J. 2000, 19:5762-5771.
64. Wu Y., Chen Y., Li L., Yu G., Zhang Y., He Y. Associations of high-risk HPV types and viral load with cervical cancer in China. J. Clin. Virol. 2006, 35:264-269.
65. Xue Y., Bellanger S., Zhang W., Lim D., Low J., Lunny D., Thierry F. HPV16 E2 is an immediate early marker of viral infection, preceding E7 expression in precursor structures of cervical carcinoma. Cancer Res. 2010, 70:5316-5325.
66. Yee C., Krishnan-Hewlett I., Baker C.C., Schlegel R., Howley P.M. Presence and expression of human papillomavirus sequences in human cervical carcinoma cell lines. Am. J. Pathol. 1985, 119:361-366.
67. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat. Rev. Cancer 2002, 2:342-350.